Research & Development
Pathology & AI
Gene expression: Page 2
Oncocyte prices $13.86M public offering to support test development, commercialization
Oncocyte intends to use the net proceeds from the offering primarily to promote the development and commercialization of VitaGraft, DetermaIO, and DetermaCNI precision diagnostic tests.
April 3, 2023
Study supports genetic testing for people with cerebral palsy
A meta-analysis of recent cerebral palsy research suggests that genetic testing could be offered as the standard procedure for people with the disorder.
March 7, 2023
Immune-response test in study detects COVID-19 with near-perfect accuracy
A test that monitors the body’s molecular response to the SARS‑CoV‑2 virus can diagnose even asymptomatic patients with near-perfect accuracy, the researchers said.
March 1, 2023
BlueStar Genomics announces rebranding as ClearNote Health, commercialization of pancreatic cancer test
The DNA-based blood test is already available in the U.S. through the ClearNote Health physician experience program.
December 22, 2022
Molecular signature in study sheds light on adjuvant radiation therapy after breast-conserving surgery
Low scores on an investigational gene molecular signature suggest similar rates of local recurrence whether or not patients received adjuvant radiation therapy after breast-conserving surgery.
December 9, 2022
Exact Sciences shares validation data for breast cancer radiation signature at SABCS
The data presented as part of SABCS’s press program were from a meta-analysis of three independent, randomized clinical trials that identified which early-stage breast cancer patients benefited from radiotherapy after breast-conserving surgery.
December 12, 2022
BillionToOne announces clinical data on NIPT for recessive conditions
The firm's Unity Screen is designed to assess fetal risk of recessive conditions such as cystic fibrosis, sickle cell disease, the thalassemias, and spinal muscular atrophy.
December 6, 2022
Agendia to present abstracts on gene expression profiling tests at 2022 San Antonio Breast Cancer Symposium
Six studies focus on the impact of Agendia's MammaPrint and BluePrint tests and their ability to unveil the underlying biology of a breast cancer patient’s tumor to inform personalized treatment decisions.
December 6, 2022
At SABCS, University of Rochester professor presents clinical trial results for Biotheranostics Breast Cancer Index
The Breast Cancer Index test is the first biomarker to be evaluated in a cohort from the Suppression of Ovarian Function Trial (SOFT), Hologic noted.
December 7, 2022
Severe COVID-19 linked in study with genetic signs of brain aging
Scientists used RNA sequencing to assess changes in gene expression profiles in the brains of COVID-19 patients and compared them to changes observed in the brains of uninfected individuals, including older people.
December 7, 2022
Exact Sciences shares rise with 15% growth in Q3 revenues
Screening segment revenue, including sales for the Cologuard colon cancer molecular test, was $360.8 million, an increase of 29% year-over-year.
November 4, 2022
At AMP 2022, Immunexpress launches rapid test for sepsis requiring two minutes hands-on time
The firm obtained FDA 510(k) clearance for its SeptiCyte Rapid test last year. The test runs on the sample-to-answer Biocartis Idylla molecular testing platform.
November 5, 2022
Page 2 of 3